Abcellera Biologics (ABCL) Stock
Antibody discovery platform partnering with drug companies. Here's the price, business snapshot, and what's worth knowing about Abcellera Biologics in June 2026.
AbCellera Biologics Inc (ABCL) is a Canadian biotechnology company that uses a high-throughput, single‑cell discovery platform to identify therapeutic antibodies. Investors should know AbCellera operates primarily as a partner‑centric platform: it discovers candidate antibodies for pharmaceutical collaborators and earns revenue through upfront fees, milestones and potential royalties. This model can generate high-value, irregular payments tied to partner progress rather than steady product sales. The company’s strengths include a proprietary discovery engine, a track record of collaborations and an expanding pipeline of partnered programmes. Key risks include timeline and clinical development uncertainty, dependence on a handful of major partners, variable revenue recognition and the capital‑intensity of biotech R&D. Valuation can be volatile and past performance is not a reliable guide to future returns. This information is general and educational, not personalised investment advice — suitability depends on an investor’s goals, time horizon and risk tolerance; values can rise and fall.
Stock Performance Snapshot
Analyst Rating
Analysts suggest buying ABCELLERA’s stock, expecting it to reach a price of $10 soon.
Financial Health
Abcellera is generating strong revenue and cash flow, indicating good financial performance and stability.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Discover More Opportunities
ACADIA PHARMACEUTICALS INC
ACADIA Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of treatments for central nervous system disorders.
ADAPTIVE BIOTECHNOLOGIES CORP
Adaptive Biotechnologies Corporation is a commercial-stage company. The Company focuses on the field of immune medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its immune medicine platform applies its technologies to read the genetic code of a patient's immune system. It operates through two segments, which include Minimal Residual Disease (MRD) and Immune Medicine. The MRD business focuses on the use of its sensitive, next-generation sequencing (NGS) assay to measure MRD in patients with hematologic malignancies. Its MRD business is comprised of its clonoSEQ clinical diagnostic testing service, offered to clinicians. Its Immune Medicine business focuses on immune-repertoire sequencing, target antigen discovery, data licensing and TCR-antigen prediction models in the identification, validation, development and adoption of products and services.
ABSCI CORP
ABSCI Corporation is a biotechnology company focused on the discovery and development of targeted immune modulators for the treatment of cancer and other diseases.
Baskets Featuring ABCL
AI Drug Discovery | Biotech Investment Opportunities
NVIDIA and Eli Lilly have launched a $1 billion AI lab to revolutionize the drug discovery process. This partnership highlights a burgeoning investment opportunity in companies at the intersection of artificial intelligence and biotechnology.
Published: January 13, 2026
Explore BasketBiotech Buyout Candidates (Post-Merck Acquisition)
Merck's $9.2 billion acquisition of Cidara Therapeutics for its antiviral drug pipeline signals a broader industry trend. This creates an investment opportunity in other biotech companies with promising late-stage drugs that could become the next acquisition targets for pharmaceutical giants.
Published: November 17, 2025
Explore BasketPharma M&A Targets: Biotech Stocks to Watch 2025
AbbVie is spending $2.7 billion on external R&D, highlighting a major industry trend of large pharmaceutical companies acquiring innovation. This creates a potential opportunity among the smaller biotech firms that are becoming prime acquisition targets.
Published: October 5, 2025
Explore BasketHope & Optimism Portfolio
This collection brings together pioneering companies working to solve humanity's biggest challenges through groundbreaking innovation. These carefully selected stocks represent visionaries building transformative technologies in medicine, energy, and beyond.
Published: June 18, 2025
Explore BasketAI-Driven Drug Discovery
These groundbreaking companies are redefining pharmaceutical research with artificial intelligence. Each has been carefully selected by our analysts for their potential to develop life-saving drugs faster and more efficiently than traditional methods allow.
Published: June 17, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Platform-driven discovery
A proprietary single‑cell platform helps find antibody leads quickly, which may speed collaborations — though discovery does not guarantee commercial success.
Partner revenue model
Revenue stems from collaborations, milestones and potential royalties, creating upside tied to partners but also irregular cash flows and dependency risks.
Development uncertainty
Clinical, regulatory and commercial hurdles can delay or derail programmes, making the stock potentially volatile and suitable for risk‑tolerant investors only.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
